Summary
- Scopus BioPharma has filed to raise $6 million in an IPO.
- The firm is advancing treatment candidates for lymphoma and systemic sclerosis.
- SCPS is thinly capitalized and is still at pre-Phase 1 stage, so the IPO is ultra-high risk.
- I'll watch the IPO from the sidelines.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Scopus BioPharma (SCPS) has filed to raise $6 million in an IPO of its common stock, according to a 1-A registration statement.
The company is developing treatments for lymphoma and systemic sclerosis conditions.
SCPS is thinly capitalized and is still at pre-clinical stage so is very early and ultra-high-risk.
Company And Technology
New York, NY-based Scopus was founded to license and develop a STAT3 inhibitor gene therapy for various cancers including B-cell lymphoma.
Scopus is also advancing a cannabinoid-1 candidate for the treatment of fibrosis of the skin, lung, kidney, heart and gastrointestinal tract, also known as systemic sclerosis.
Management is headed by Co-Chairman Mr. Paul Hopper, who was previously Executive Chairman of Bioscience Oncology Pty and has played senior roles at several private and publicly-traded biopharma firms in the U.S. and Australia.
Below is a brief overview video of non-Hodgkin lymphoma:
